Careers: Join Our Team
Venture Lead/Entrepreneur in Residence
The Venture Lead (VL) will work with Aditum Bio partners to define interesting targets and mechanisms of action across a range of therapeutic areas, taking a proactive approach to identification of new therapies. The VL will research and define these areas of interest, working with external scientific and clinical experts, as well as the internal Aditum Bio team. The VL can be a project based or part time role.
Research on potential therapies: Research and define interesting mechanisms of action in a given therapeutic area through a combination of literature search, discussions with leading clinical and scientific investigators and market research. Develop a summary presentation, prioritizing 5-10 top pathways of interest.
Project meetings and iterations: Work closely with Aditum Bio partners and scientific advisors to discuss interim findings. Use discussions and feedback to iterate on research and recommendations.
Presentations and discussions: Facilitate and join scientific panels to review the VL’s selected 5-10 pathways developed, with discussions incorporating leading external researchers and clinicians in the field.
Mentorship and Leadership opportunities: Gain exposure to biotech investing, venture capital and biotech operations across a range of Aditum Bio Partners and Operators. Develop opportunities to stay with a new biotech formed as a Scientific Co-Founder.
This is a remote working opportunity with the expectation to meet in person easily if needed for important meetings and occasions in the San Francisco Bay Area or in the Boston/Cambridge area.
Aditum Bio is a new model of biotech venture capital uniquely positioned to rapidly translate scientific discoveries into innovative new medicines. Aditum brings together unmatched scientific and domain expertise, combined with operational capabilities. Our agile operating model enables rapid company formation, planning, and execution for a new model of drug development. We target clinic-ready therapies to help underserved patient populations, rapidly forming companies and staffing them with medical and scientific experts. Launched in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, Aditum currently manages a broad portfolio of clinical stage companies with multiple drug candidates entering Phase 2 clinical trials in 2022.
Aditum Bio provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.